MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Icke, C.
Right arrow Articles by Glusa, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Icke, C.
Right arrow Articles by Glusa, E.

Vol. 62, Issue 2, 203-209, August 2002

Fusion Proteins with Anticoagulant and Fibrinolytic Properties: Functional Studies and Structural Considerations

Christian Icke, Bernhard Schlott, Oliver Ohlenschläger, Manfred Hartmann, Karl-Heinz Gührs, and Erika Glusa

Friedrich-Schiller-Universität Jena, Zentrum für Vaskuläre Biologie und Medizin, Erfurt, Germany (C.I., E.G.); and Institut für Molekulare Biotechnologie e.V., Jena, Germany (B.S., O.O., M.H., K.-H.G.)

In an effort to combine the benefits of fibrinolytics, such as staphylokinase, with those of thrombin inhibitors for the prevention of vessel reocclusion after vascular injury, we have produced several chimeric proteins with plasminogen-activating and thrombin-inhibiting properties. Fusion proteins were constructed consisting of the modules staphylokinase (Sak), the factor Xa cleavage site, and various dipetalin (Dip) domains (H6-Sak-Dip-I+II, H6-Sak-Dip-I, and H6-Sak-Dip-II). Sak stimulates fibrinolysis via activation of plasminogen, whereas dipetalin is a two-domain, Kazal-type inhibitor of thrombin. NMR spectroscopy of the fusion proteins revealed that the molecular structures of the modules are retained in the fusion protein and that no significant interactions occur between the modules in terms of their functionally relevant regions. In enzymatic thrombin inhibition tests and blood coagulation assays (thrombin, prothrombin, and activated partial thromboplastin times), no significant differences in anticoagulant capacity were observed between the fusion protein H6-Sak-Dip-I+II and isolated Dip-I+II, even at nanomolar concentrations. Similar results (i.e., the inhibition of thrombin-induced platelet aggregation and the inhibition of thrombin-induced vascular relaxation) were obtained when the cellular thrombin effects were studied. The fusion protein containing Dip-I has less but still significant thrombin inhibitory effects compared with those of H6-Sak-Dip-I+II. In contrast, the H6-Sak-Dip-II protein failed to inhibit thrombin in each of the assays used. The plasminogen-activating and fibrinolytic activities of the fusion proteins are similar to those of wild-type Sak. The individual dipetalin domains do not activate plasminogen. In conclusion, the fusion protein H6-Sak-Dip-I+II is a bifunctional molecule able to activate fibrinolysis via plasminogen activation and inhibit blood coagulation via direct inhibition of thrombin.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Wong Po Foo, S. V. Patwardhan, D. J. Belton, B. Kitchel, D. Anastasiades, J. Huang, R. R. Naik, C. C. Perry, and D. L. Kaplan
Novel nanocomposites from spider silk-silica fusion (chimeric) proteins
PNAS, June 20, 2006; 103(25): 9428 - 9433.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S.-C. Wu, F. J. Castellino, and S.-L. Wong
A Fast-acting, Modular-structured Staphylokinase Fusion with Kringle-1 from Human Plasminogen as the Fibrin-targeting Domain Offers Improved Clot Lysis Efficacy
J. Biol. Chem., May 9, 2003; 278(20): 18199 - 18206.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics